AttributesValues
type
value
  • The oncology community is concerned that cancer patients will be unfairly classified in pandemic allocation guidances. Past guidances either excluded metastatic cancer patients from consideration or categorized them as having a survival of less than one year. Given recent improvements in treatments, we recommend that (1)the prognosis of an individual cancer patient be determined with input from a cancer specialist, or (2) if this is impractical, (a) The presence of active metastatic solid cancer or relapsed hematologic malignancy is graded as a major comorbidity, with a likelihood that survival will be less than 5 years; (b) Severe limitation in physical functioning (3 or 4 on the Eastern Cooperative Oncology Group performance status (ECOG‐PS) would define an advanced cancer patient as having a severe comorbidity, with a likelihood of less than 1 year survival. Cancer may be the “Emperor of all Maladies,” but it is no longer a certain death sentence.
subject
  • Oncology
  • Quality of life
  • Hematologic malignant neoplasms
  • Medical research institutes in the United States
  • Medical scoring system
  • Cancer pathology
  • Mental and behavioural disorders
  • Cancer organizations based in the United States
  • Organizations established in 1955
  • Medical and health organizations based in Massachusetts
  • 1955 establishments in the United States
  • Clinical trial organizations
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software